Patents by Inventor Qiuping Luo

Qiuping Luo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYANO-SUBSTITUTED CYCLIC HYDRAZINE DERIVATIVE AND APPLICATION THEREOF
    Publication number: 20220339146
    Abstract: The present invention provides a cyano-substituted cyclic hydrazine derivative, comprising: a compound represented by the following structural formula or a stereoisomer, a geometric isomer, a tautomer, a racemate, a hydrate, a solvate, a metabolite and a pharmaceutically acceptable salt or a prodrug thereof. The compound is used for prevention, treatment or alleviation of autoimmune diseases or proliferative diseases in patients, and/or for inhibiting or modulating protein kinase activity.
    Type: Application
    Filed: June 11, 2020
    Publication date: October 27, 2022
    Applicant: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd
    Inventors: Wang SHEN, Pengfei LIU, Rujun BAI, Yufei LIU, Qiuping LUO, Pingbo KE, Yanchuan GONG
  • Anti-inflammatory compound, and preparation and use thereof
    Patent number: 11440886
    Abstract: The present invention provides an anti-inflammatory compound, which is a compound having a structure (I) as shown below: The compound is a target that is important for autoimmune activation, and that has strong inhibitory effect on PDE4 and penetrates the skin easily, and is a new type anti-inflammatory compound that is easily degraded.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: September 13, 2022
    Assignee: E-Nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
    Inventors: Wang Shen, Pengfei Liu, Jinping Zhu, Qiuping Luo, Pingbo Ke, Yufei Liu, Jida Shen
  • ANTI-INFLAMMATORY COMPOUND, AND PREPARATION AND USE THEREOF
    Publication number: 20200377460
    Abstract: The present invention provides an anti-inflammatory compound, which is a compound having a structure (I) as shown below: The compound is a target that is important for autoimmune activation, and that has strong inhibitory effect on PDE4 and penetrates the skin easily, and is a new type anti-inflammatory compound that is easily degraded.
    Type: Application
    Filed: August 14, 2020
    Publication date: December 3, 2020
    Applicant: VivaVision Biotech, Inc.
    Inventors: Wang Shen, Pengfei Liu, Jinping Zhu, Qiuping Luo, Pingbo Ke, Yufei Liu, Jida Shen